More than 25 merger and acquisition activities have been executed in the biotech industry in It is very likely that this trend will also continue in There are a lot of buyout rumors in the news about potential biotech takeover candidates. Here is a list of our top merger and acquisition candidates. But are these also the best stocks to buy now? Myovant Sciences. Myovant Sciences is a small pharmaceutical company which was founded in In Aprilthe company entered into a license agreement with Takeda Pharmaceutical and was thereby granted with the exclusive and worldwide rights excluding Japan and other Asian countries to develop and commercialize Relugolix, a small molecule antagonist of the gonadotropin-releasing hormone GnRH receptor.
Since then, Myovant has successfully established Relugolix as a potential blockbuster drug in two different markets. Firstly, Relugolix is being developed for the treatment of men with androgen-sensitive prostate cancer. Secondly, Relugolix has also been tested as a treatment for so-called uterine fibroids. Uterine fibroids are non-cancerous tumors which develop inside the uterine wall, a condition which might result in excessive bleeding.
Relugolix has demonstrated significant improvements of this bleeding activity in another phase 3 trial in After a potential approval of Relugolix by healthcare authorities which we expect to happen during this or next year, Myovant will be competing with much larger pharmaceutical companies such as AbbVie or AstraZeneca in both, the prostate as well as the uterine fibroid market.
From our experience, it is exactly the combination of these two factors which make Myovant an ideal takeover target for larger pharmaceutical companies. Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is specialized on precision oncology. Inthe company dominated the headlines with strong results for its cancer drug Ripretinib. Ripretinib showed convincing efficacy and safety data in patients with gastrointestinal stromal tumors GIST.
Deciphera now plans to file a new drug application for Ripretinib in the first quarter of In addition, Deciphera has a highly promising pipeline with various drug candidates. The company is still the only owner of the rights for the development and commercialisation of these pipeline projects, making Deciphera a very interesting takeover target for a potential buyer.
Clovis Oncology. Rubraca has been approved in and is currently being investigated in a number of additional clinical trials for indications such as breast, prostate, pancreatic, or lung cancer. Axsome Therapeutics. Alexion Pharmaceuticals. Takeover rumors around Alexion Pharmaceuticals exist already since a few years. The specialist for rare disease drugs would be an ideal partner for big pharmaceuticals such as Novartis, Amgen, or Pfizer.
Incyte has a very attractive drug portfolio. Jakafi, a drug for the treatment of rare blood cancers, already reached blockbuster status. With Olumiant and Iclusig, the company has two additional drugs on the market. A third will most likely follow in as we expect the FDA approval for Pemigatinib for the treatment of cholangiocarcinoma during the second quarter of Sarepta Therapeutics.
Gene therapy companies have been popular takeover targets in the past. Roche just received the go-ahead for the acquisition of the US gene therapy player Spark Therapeutics. Sarepta Therapeutics is one of the next gene therapy specialists that could get taken out.
The company has several gene therapies for the treatment of Duchenne muscular dystrophy and makes major efforts to expand its pipeline to other neurologic conditions. Amarin is a pharmaceutical company focusing on the development of novel therapeutics for cardiovascular diseases. With Vascepa, the company has already an FDA-approved drug. In Decemberthe label of Vascepa was extended to a broader use.Yesterday, the conglomerate received a green signal from the U.
With this, it completed all requirements for getting antitrust clearances for the buyout. Notably, Danaher announced the buyout deal in February The BioPharma business comprises single-use technologies, process chromatography hardware and related consumables, development instrumentation and related consumables, cell culture media and service.
Inside the Headlines Danaher also noted that the buyout received clearances from the European Commission as well as antitrust authorities of Korea, Brazil, Russia, China, Israel and Japan. The transaction is anticipated to close on Mar 31, after the fulfillment of conditions mentioned in the purchase agreement. Also, it will assume certain pension liabilities of General Electric.
Post the completion of the buyout, Danaher will integrate the BioPharma business with its Life Sciences segment. Earnings accretion of 60 cents per share is anticipated in disclosed in January from the buyout.
Previously, Danaher had expected cents per share earnings accretion in the first year of the deal completion. Danaher acquired Labcyte Corporation in January The company is poised to benefit from product innovation, Danaher Business System, shareholder-friendly policies and inorganic initiatives. However, forex woes, high costs and huge debts remain concerning.
In the past 30 days, the Zacks Consensus Estimate for its earnings has been lowered by 2. Danaher Corporation Price and Consensus. Both stocks currently carry a Zacks Rank 2 Buy. In the past 30 days, earnings estimates for Griffon have improved for the current year, while have been unchanged for Hitachi. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? This outperformance has not just been a recent phenomenon.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research.
Danaher to Soon Close BioPharma Buyout, Receives FTC Approval
Related Quotes. Danaher Corporation. General Electric Company. Sign in. Sign in to view your mail. Finance Home. Zacks Equity Research. Zacks March 20, View photos.
Recently Viewed Your list is empty. What to Read Next. Simply Wall St. American City Business Journals.RTTNews - saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals.
Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Like the Medicines Co. Vascepa secured its first FDA approval in for treating patients with very high triglyceride levels and as recently as yesterday Dec.
Alexion Pharma is no stranger to takeover rumors.
This developer of rare disease drug Soliris has been in acquisition crosshairs since - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. In Augustrumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.
But that deadline has long passed. Meanwhile, earlier this month, U. However, the Company has turned down Elliott's recommendation. BioMarin is almost every analyst's favorite takeover candidate.
This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Inthere were reports that Roche was eyeing BioMarin for a possible acquisition. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia.
The review of the application by the EMA is expected to commence in January under accelerated assessment. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Takeover rumors initially swirled around Clovis Oncology in when Rubraca, was in clinical trial stage.
Now, it is three years since the PARP inhibitor has been approved. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term.
Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline.
But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts.
If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. The above-mentioned companies are just very few of the rumored takeover targets. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality.
Oncology and gene therapy were the subjects of acquisitions this year. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Markets ALXN. Latest Markets Videos. See more videos. Your Watchlist is empty. Add a Symbol. Add a symbol to your watchlist.Driven to transform the lives of patients and families affected by diseases of the complement alternative pathway. At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system.
Scientific and clinical evidence has implicated the complement system, and specifically the complement alternative pathway AP in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
We are actively assessing two clinical stage, oral factor D inhibitors, danicopan ACH and, second-generation, ACH in Phase 2 and 1 studies, respectively. Achillion Pharmaceuticals.
Learn More. Achillion Pharmaceuticals At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system.
Complement Mediated Diseases. Our Science. Patients and Clinicians. Achillion has been acquired by Alexion Pharmaceuticals, Inc. For more information, click here. Achillion Pharmaceuticals, Inc.Transactions are recorded by the highest transaction dollar value rather than using the inflation adjusted values.
From Wikipedia, the free encyclopedia. Wikipedia list article. Retrieved 6 January Retrieved 27 November May 9, — via uk. Crackdown on Inversions". The New York Times. September 6, — via www. September 14, — via www. Seeking Alpha. GEN News Highlights. April 21, Retrieved April 21, April 8, Pharmaceutical Processing. Associated Press.
2 Top Biotech Buyout Candidates
Glaxo Wellcome plc. SmithKline Beecham. Merger formed GlaxoSmithKline. Bristol-Myers Squibb. Allergan, Inc. Takeda Pharmaceutical. Teva Pharmaceutical Industries. Abbott Laboratories. St Jude Medical. Astra AB. Boston Scientific Abbott Laboratories. Forest Laboratories. Genzyme Corporation. IMS Health. Merger formed QuintilesIMS. Merck Group.Today more than ever, cannabidiol CBD is becoming a trendy medical marijuana treatment. However, what some people might not know…. Keeping you up to date on federal and state policy changes and other news from the world of cannabis.
Many patients who use medical marijuana take it as an alternative to prescription drugs. If you want to take cannabis…. Cannabidiol CBD grew in popularity during the last few years until it became the health trend you see today. More and more states have moved to allow marijuana for medical or recreational use. In the expectation of treating depression….
Vaporizers are electronic devices that are used without actively smoking to inhale cannabis vapors. Vaporizers heat up the mixture of…. FSD Pharma Inc. Announces intent to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP micro-PEA during 1Q20…. Skip to content.
Home About Me Contact Me. December 13, fsdadmin Leave a comment. December 12, fsdadmin Leave a comment. December 11, fsdadmin Leave a comment. December 10, fsdadmin Leave a comment. December 9, fsdadmin Leave a comment.
December 6, fsdadmin Leave a comment. December 5, fsdadmin Leave a comment. December 4, fsdadmin Leave a comment. December 3, fsdadmin Leave a comment. December 2, fsdadmin Leave a comment.Mergers and acquisitions can be extremely profitable for pharmaceutical investors.
Here's why. Biogen's name hasn't floated to the top of many buyout rumor mills lately, and perhaps for good reason.
Biogen may prove to be an attractive target for two reasons.Pharma Industry News @04 July 2019 - PharmaState
Put simply, that's a great price for a bolt-on acquisition that should be accretive to earnings right away, and there simply aren't a whole lot of similar valuation scenarios floating around the industry these days. Second, Biogen has two particular assets under its roof that might trigger a buyout. If approved, this drug could turn out to be the best-selling medicine of all time by a wide margin.
The downside is that aducanumab belongs to a class of drugs that have repeatedly failed to show any signs of efficacy in pivotal-stage trials -- meaning that this drug is without a doubt a long shot.
Still, big pharma has plowed literally billions into similar drugs time and again -- despite any lack of proof that they work. So it shouldn't come as a shock if aducanumab turns out to be a key reason Biogen gets taken out. Spinraza is an especially attractive asset for a potential acquirer because it's an orphan medication, so it comes with an extended period of exclusivity, and it will probably turn out to be largely immune to any potential drug pricing reforms.
The overarching reason is obvious: Opdivo. Despite the tenacity of these rumors, however, Bristol has yet to receive a formal offer -- at least one that's been made public. Presumably, potential suitors are concerned about Opdivo's ability to break into earlier lines of therapy for its most valuable indication -- non-small cell lung cancer NSCLC -- and to stave off competitors in later-line settings as well. Opdivo, after all, flamed out in a clinical trial as a monotherapy for NSCLC and its ongoing combination study with Bristol's Yervoy is showing some worrisome signs as well.
The bigger picture, though, is that Bristol is without question transforming into an immuno-oncology giant, regardless of this hiccup in NSCLC.
That's an enormously appealing feature to a company that has largely failed to establish its own oncology franchise like Gilead. As an added bonus, Bristol also sports two additional legit franchise-level drugs.
But Pfizer is a definite contender to make a play for Bristol based on their shared interests in immuno-oncology, cardiovascular care, and anti-inflammatory diseases. Stay tuned. Although you should arguably never buy a stock simply because of its potential as a buyout candidate, there's no denying that another wave of consolidation is eventually going to sweep across the biopharmaceutical landscape soon.
So it's probably a good idea to at least have this secondary value driver in the back of your mind when buying biotech and biopharma stocks right now.
In regards to Biogen and Bristol, these two companies both offer modest near-term growth prospects, fairly clean balance sheets, and some intriguing clinical assets. As such, a buyout thesis certainly isn't necessary in order to consider adding these top pharma names to your portfolio.